Liquidia Technologies

Liquidia Technologies

Yahoo Finance • 6 days ago

IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?

The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers lower fees and a higher dividend yield, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) spreads its holdings more evenly across the sector's biggest players. Investors seeking... Full story

Yahoo Finance • last month

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

Liquidia Technologies, Inc. MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respira... Full story

Yahoo Finance • last month

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the... Full story

Yahoo Finance • last month

Marvell stock pops after S&P 500 inclusion announcement

Investing.com -- Marvell Technology Inc (NASDAQ:MRVL) shook off a sharp two-day slump in postmarket trade Friday following the announcement of its upcoming inclusion in the bellwether S&P 500 index. Shares of the semiconductor company boun... Full story

Yahoo Finance • last month

Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics

[Supreme Court of the United States. Washington DC, USA.] Mindaugas Dulinskas The Supreme Court unanimously sided with generic drugmaker Hikma (HKMPF [https://seekingalpha.com/symbol/HKMPF]) and against Amarin Corp. (AMRN [https://seeking... Full story

Yahoo Finance • last month

State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?

The State Street SPDR S&P Pharmaceuticals ETF(NYSEMKT:XPH) offers a lower-cost entry into the drug manufacturing space, while the First Trust NYSE Arca Biotechnology Index Fund(NYSEMKT:FBT) provides concentrated exposure to biotechnology.... Full story

Yahoo Finance • 2 months ago

Liquidia targets at least $1B net revenue in 2027 as YUTREPIA Q1 net product sales rise 44% sequentially

Earnings Call Insights: Liquidia (LQDA) Q1 2026 MANAGEMENT VIEW * "Three full quarters into the commercial launch of YUTREPIA, I would summarize the state of our business with 3 main points" (CEO & Director Roger Jeffs). "YUTREPIA is n... Full story

Yahoo Finance • 2 months ago

Liquidia Q1 Earnings Call Highlights

Liquidia logo MarketBeat Week in Review: 12/25 - 12/29 Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial h... Full story

Yahoo Finance • 2 months ago

Liquidia (LQDA) Shares Rise After Strong Q1 Earnings and Revenue Beat

medical research 16 ©Rawpixel Liquidia Corporation (NASDAQ:LQDA) shares gained nearly 3% in premarket trading on Monday after the biopharmaceutical company reported first-quarter results that exceeded analyst expectations on both earnings... Full story

Yahoo Finance • 2 months ago

This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth

On May 8, 2026, JW Asset Management reported selling 83,600 shares of Liquidia Corporation(NASDAQ:LQDA), an estimated $3.10 million trade based on quarterly average pricing. What happened According to an SEC filing dated May 8, 2026, JW... Full story

Yahoo Finance • 3 months ago

Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million

Roger Jeffs, Chief Executive Officer of Liquidia, disclosed the indirect sale of 53,300 shares of common stock through Serendipity BioPharma LLC, generating approximately $2.14 million in proceeds, according to an SEC Form 4 filing. Trans... Full story

Yahoo Finance • 3 months ago

Wells Fargo Lifts PT on Liquidia Corporation (LQDA) to $51 From $44 – Here’s Why

Liquidia Corporation (NASDAQ:LQDA) is one of the best high growth healthcare stocks to buy now. Wells Fargo raised the price target on Liquidia Corporation (NASDAQ:LQDA) to $51 from $44 on March 23, reiterating an Overweight rating on the... Full story

Yahoo Finance • 3 months ago

The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M

Liquidia(NASDAQ:LQDA) Chief Commercial Officer Scott Moomaw reported the exercise and immediate sale of 80,000 shares of common stock, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 80,000 Transac... Full story

Yahoo Finance • 4 months ago

Mid-Cap healthcare stocks ranked by quant ratings after earnings season

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of co... Full story

Yahoo Finance • 4 months ago

Dave Stock Soars 150% in a Year as Newly Disclosed $7 Million Buy Signals Confidence in Fintech Upstart

On February 17, 2026, Findell Capital Management disclosed a buy of 32,000 shares of Dave(NASDAQ:DAVE) in the fourth quarter, with the estimated transaction value at $6.88 million based on the quarterly average price. What happened Accor... Full story

Yahoo Finance • 4 months ago

United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says

United Therapeutics (UTHR) remains a "top pick" due to several near- to medium-term catalysts that c PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Liquidia GAAP EPS of $0.15 misses by $0.05, revenue of $92.02M beats by $4.53M

* Liquidia press release [https://seekingalpha.com/pr/20425170-liquidia-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides] (LQDA [https://seekingalpha.com/symbol/LQDA]): Q4 GAAP EPS of $0.15 misses by $... Full story

Yahoo Finance • 4 months ago

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February... Full story

Yahoo Finance • 4 months ago

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing

Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Happened According to a SEC filing dated... Full story

Yahoo Finance • 5 months ago

Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)

Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside. On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) with a $96 price target. His estima... Full story